The Potential of Carnosine in Brain-Related Disorders: A Comprehensive Review of Current Evidence

Nutrients

Jozef Ukropec¹  Barbara Ukropcová²  Martin Schön²  WernL. Chia³  Barbora de Courten³  Aya Mousa³  Michael Berk⁴  Arshad Majid⁵ 

[1] Biomedical Research Center, Slovak Academy of Sciences, 81439 Bratislava, Slovakia;Institute of Pathophysiology, Faculty of Medicine, Comenius University, 84215 Bratislava, Slovakia;Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, Melbourne, VIC 3168, Australia;School of Medicine, IMPACT Strategic Research Centre, Barwon Health, Deakin University, Geelong, VIC 3220, Australia;Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield S10 2HQ, UK;

关键词: carnosine;    L-histidine;    β-alanine;    brain;    cognition;    treatment;    psychiatry;    neurology;    nervous system;   

DOI  :  10.3390/nu11061196

来源: DOAJ

【 摘 要 】

Neurological, neurodegenerative, and psychiatric disorders represent a serious burden because of their increasing prevalence, risk of disability, and the lack of effective causal/disease-modifying treatments. There is a growing body of evidence indicating potentially favourable effects of carnosine, which is an over-the-counter food supplement, in peripheral tissues. Although most studies to date have focused on the role of carnosine in metabolic and cardiovascular disorders, the physiological presence of this di-peptide and its analogues in the brain together with their ability to cross the blood-brain barrier as well as evidence from in vitro, animal, and human studies suggest carnosine as a promising therapeutic target in brain disorders. In this review, we aim to provide a comprehensive overview of the role of carnosine in neurological, neurodevelopmental, neurodegenerative, and psychiatric disorders, summarizing current evidence from cell, animal, and human cross-sectional, longitudinal studies, and randomized controlled trials.

【 授权许可】

Unknown